15 investors back Shanghai healthtech in 2026. Shanghai is China's biopharma capital. Bio-specialist funds and pharma giants lead, as licensing deals boom.
Shanghai is China's biopharma capital, with Zhangjiang serving as its pharma valley. Bio-specialist funds lead the money here, and pharma giants back the drugs too.
Chinese drugs now sell to global pharma, and licensing deals have hit records. Cheques run from US$5M to US$300M, while pharma deals can run larger still.
State health funds anchor many rounds, and Pudong's capital pools run deep. The mix of capital here is rare, since few cities pair such deep science with this much money.
Health rounds run on data and trials, so the paperwork matters as much as the pitch. Ellty keeps your files in one tracked room, ready for every fund that asks.
| Type | Check size | Sector focus | Website | |
|---|---|---|---|---|
| Lilly Asia Ventures | Bio / health VC | US$10M-$100M+ | Biopharma, med-tech, diagnostics | lavfund.com |
| Qiming Venture Partners | VC (large bio book) | US$5M-$50M+ | Biotech, AI drugs, devices | qimingvc.com |
| OrbiMed Asia | Healthcare fund | US$10M-$100M+ | Biotech, pharma, devices | orbimed.com |
| CBC Group | Healthcare PE | US$30M-$300M | Biotech, devices, health services | cbridgecap.com |
| 6 Dimensions Capital | Healthcare VC | US$5M-$50M | Biotech, diagnostics, devices | 6dimensionscapital.com |
| Vivo Capital | Healthcare VC / PE | US$10M-$100M | Biotech, pharma, devices | vivocapital.com |
| Pivotal bioVenture China | Biotech VC | US$5M-$30M | Therapeutics, devices, services | pivotalbiovp.cn |
| Sherpa Healthcare Partners | Healthcare VC | US$5M-$40M | Biotech, life science, healthtech | sherpahp.com |
| Shanghai Healthcare Capital | State life-sciences fund | Large state fund | Biotech, devices, health services | Shanghai state fund |
| Zhangjiang / Pudong VC | State / government fund | LP + direct | Biomedicine, Pharma Valley firms | Shanghai state fund |
| AstraZeneca | Pharma CVC / strategic | Strategic | Biotech, AI discovery, cell therapy | astrazeneca.com |
| Eli Lilly | Pharma strategic | Strategic / licensing | Drugs, AI drug discovery | lilly.com |
| Fosun Pharma | Pharma corporate | Strategic / M&A | Biopharma, innovative drugs | fosunpharma.com |
| WuXi AppTec | CRO/CDMO + co-invest | Strategic / co-invest | Drug R&D services, biotech | wuxiapptec.com |
| Decheng Capital | Healthcare VC | US$10M-$80M | Biotech, drugs, devices | dechengcapital.com |
Keep your trial data room ready for every fund
Health funds run long diligence on trials, IP, and approvals. Ellty logs every view so you know who is serious before the call.
Start free 14-day trialWhat a healthtech investor backs
A healthtech investor backs proof and safety, and they want real clinical data behind every claim. They check your trials, approvals, and IP, and most run a deep venture capital check before they commit.
They study both your science and your team, and a clean due diligence file helps a lot. They weigh your regulatory path closely, because NMPA timing can make or break a round.
They also look for a clear market need, since a drug must beat what doctors already use today. Ellty gives each fund one tracked link to your data, so you see who read your trial data first.
The total value of these licensing-out deals is on track to double again over the next 18 to 24 months.
15 Shanghai healthtech investors
1. Lilly Asia Ventures
LAV is one of China's top life-science VCs.
Recent Activity: Closed a US$700M bio fund in 2025
Sector Focus: Biopharma, med-tech, diagnostics
Stage Focus: Series A to C
Check Size: US$10M-$100M+
Location: Shanghai
Website: lavfund.com
2. Qiming Venture Partners
Qiming holds a large healthcare and biotech book.
Recent Activity: Backed AI-drug firm Insilico before its IPO
LinkedIn: Qiming Venture Partners LinkedIn
Sector Focus: Biotech, AI drugs, devices
Stage Focus: Early to growth
Check Size: US$5M-$50M+
Location: Shanghai
Website: qimingvc.com
3. OrbiMed Asia
OrbiMed is a dedicated healthcare investment firm.
Recent Activity: Raising a ~US$1.1B Asia healthcare fund
Sector Focus: Biotech, pharma, devices
Stage Focus: Early to growth
Check Size: US$10M-$100M+
Location: New York / Shanghai
Website: orbimed.com
4. CBC Group
CBC is Asia's largest healthcare investor.
Recent Activity: Closed a ~US$980M RMB healthcare fund
Sector Focus: Biotech, devices, health services
Stage Focus: Growth, buyout
Check Size: US$30M-$300M
Location: Singapore / Shanghai
Website: cbridgecap.com
5. 6 Dimensions Capital
6 Dimensions is a US-China healthcare VC.
Recent Activity: Backed Halda, sold to J&J for US$3B
Sector Focus: Biotech, diagnostics, devices
Stage Focus: Early to growth
Check Size: US$5M-$50M
Location: Shanghai
Website: 6dimensionscapital.com
6. Vivo Capital
Vivo backs Chinese biotech from an RMB fund.
Recent Activity: Closed a ~US$600M yuan healthcare fund
Sector Focus: Biotech, pharma, devices
Stage Focus: Growth
Check Size: US$10M-$100M
Location: US / China
Website: vivocapital.com
Share one link with every health fund
Ellty shows when LAV or Qiming opens your trial data. Follow up with each fund at the right time.
Start free 14-day trial7. Pivotal bioVenture China
Pivotal runs an early-stage China life-science fund.
Recent Activity: Runs a US$150M early-stage bio fund
Sector Focus: Therapeutics, devices, services
Stage Focus: Early-stage
Check Size: US$5M-$30M
Location: China
Website: pivotalbiovp.cn
8. Sherpa Healthcare Partners
Sherpa is an active China biotech investor.
Recent Activity: An active China biotech investor in 2025
Sector Focus: Biotech, life science, healthtech
Stage Focus: Early to growth
Check Size: US$5M-$40M
Location: Beijing
Website: sherpahp.com
9. Shanghai Healthcare Capital
This is Shanghai's state life-sciences fund.
Recent Activity: A state fund targeting RMB 50B
Sector Focus: Biotech, devices, health services
Stage Focus: Early to late
Check Size: Large state fund
Location: Shanghai
Website: Shanghai state fund
10. Zhangjiang / Pudong VC
These state funds seed the Pharma Valley cluster.
Recent Activity: Put ~RMB 6B into biomedicine funds
Sector Focus: Biomedicine, Pharma Valley firms
Stage Focus: Fund LP, direct
Check Size: LP + direct
Location: Shanghai
Website: Shanghai state fund
11. AstraZeneca
AstraZeneca runs a big Shanghai R&D base and fund.
Recent Activity: Co-led a US$100M round for Syneron Bio
LinkedIn: AstraZeneca LinkedIn
Sector Focus: Biotech, AI discovery, cell therapy
Stage Focus: Strategic, growth
Check Size: Strategic
Location: Shanghai R&D
Website: astrazeneca.com
12. Eli Lilly
Eli Lilly backs and licenses Chinese drug work.
Recent Activity: An AI-drug partner with Shanghai's XtalPi
LinkedIn: Eli Lilly LinkedIn
Sector Focus: Drugs, AI drug discovery
Stage Focus: Strategic, licensing
Check Size: Strategic / licensing
Location: US / China
Website: lilly.com
13. Fosun Pharma
Fosun Pharma is Shanghai's big drug maker.
Recent Activity: Grew innovative-drug sales 30% in 2025
Sector Focus: Biopharma, innovative drugs
Stage Focus: Strategic, M&A
Check Size: Strategic / M&A
Location: Shanghai
Website: fosunpharma.com
14. WuXi AppTec
WuXi is Shanghai's drug R&D and CDMO giant.
Recent Activity: A drug R&D giant; co-bought biotech Ambrx
LinkedIn: WuXi AppTec LinkedIn
Sector Focus: Drug R&D services, biotech
Stage Focus: Strategic, co-invest
Check Size: Strategic / co-invest
Location: Shanghai
Website: wuxiapptec.com
15. Decheng Capital
Decheng is a US-China healthcare VC.
Recent Activity: A China-US healthcare VC in biotech
Sector Focus: Biotech, drugs, devices
Stage Focus: Early to growth
Check Size: US$10M-$80M
Location: Shanghai
Website: dechengcapital.com
Zhangjiang, China's pharma valley
Zhangjiang is China's pharma valley, where thousands of biotech firms cluster together. Pudong runs huge state health funds that seed and grow these local firms.
A valley address can unlock state grants, and it brings labs and CRO partners within reach. The talent pools here run deep too, with top scientists sitting just minutes apart.
The cluster keeps growing each year, as new labs and incubators open all the time. Strong investor relations help here, and you can see our Shanghai AI investors guide too.
Investors want clean trial data early, well before they sit down at the table. Ellty keeps every file in one place, so nothing slips through the cracks.
The biotech licensing boom
Chinese biotech is now globally strong, licensing drugs to big pharma in deals that hit records in 2025. A single licensing deal can fund a whole trial and bring in a global partner, while the upfront payment de-risks your next round.
Those upfront payments also validate your science to local funds, and each deal draws more capital to Shanghai. The cycle of capital and proof feeds itself, pulling fresh money toward the cluster with every signing.
Trial and IP data is sensitive, so use granular permissions on each file you share. Ellty controls who opens each file, and you see exactly who studied your data.
From lab to a funded scale-up
Biotech often starts in a lab, and the path to market from there is long. Investors check trials, approvals, and IP, because early data alone rarely closes a round.
A clean trial file speeds the deal up, so have it ready before the term sheet lands. Milestones between rounds prove momentum, and each readout lifts your next valuation.
A strong team also de-risks the bet, since investors back people as much as data. Read our due diligence for investors guide to know what each backer will ask.
Learn how to prepare for due diligence early, before the first fund digs in. Ellty logs who opened each file and when, so your follow-up always lands at the right moment.
How to pitch a Shanghai healthtech investor
Lead with real clinical proof.
- 1.Lead with real clinical proof.Health funds back hard data, so open with your strongest trial readout. Make the result clear in the first minute, before any market slides.
- 2.Show trials, approvals, and IP.Safety and science come first, so map your approvals and patents clearly. Walk each fund through your NMPA path and the IP that protects it.
- 3.Share one Ellty link to your data room.Skip email attachments and track who opens which file in real time. One link keeps every version current and every fund on the same page.
- 4.Follow up the day a fund digs in.Ellty flags the moment they open your data, so you reach out fast. A timely nudge while interest is hot keeps the deal moving forward.
How Ellty helps you land a healthtech investor in Shanghai
You've shortlisted your Shanghai healthtech investors already. Set up a data room before the first call.
- 1.Upload your trial data, IP, and deck.Set access per fund or per partner.
- 2.Share one trackable link with each fund.Each fund gets its own tracked link.
- 3.Watch opens and follow up at the right time.Use Ellty analytics to time each nudge.
Shanghai healthtech investor questions
- LAV, Qiming, and OrbiMed back health. Pharma giants invest too.
- Zhangjiang is China's pharma valley. Thousands of firms cluster there.
- Chinese drugs now sell to big pharma. Deals hit records in 2025.
- Cheques run US$5M to US$300M in 2026. Pharma deals can run larger.
- Clinical proof, IP, and a clear path. Strong science and a team.
- Before your very first investor call. Track who opens your trial data.
